Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling

Simply Wall St.07-01

U.S. federal appellate court rules that Ardelyx’s Xphozah will be included in Medicare’s ESRD bundled payment system, ending separate reimbursement. The decision resolves a long-running legal dispute ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648759314?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-01 07:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648759314","market":"us","top_or_hot":-1,"title":"Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling","media":"Simply Wall St.","content":"<div>\n<p>U.S. federal appellate court rules that Ardelyx’s Xphozah will be included in Medicare’s ESRD bundled payment system, ending separate reimbursement. The decision resolves a long-running legal dispute ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-ardx-faces-new-medicare-rules-for-xphozah-after-cour\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArdelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-01 07:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-ardx-faces-new-medicare-rules-for-xphozah-after-cour><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. federal appellate court rules that Ardelyx’s Xphozah will be included in Medicare’s ESRD bundled payment system, ending separate reimbursement. The decision resolves a long-running legal dispute ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-ardx-faces-new-medicare-rules-for-xphozah-after-cour\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-ardx-faces-new-medicare-rules-for-xphozah-after-cour","article_id":"2648759314","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-ardx-faces-new-medicare-rules-for-xphozah-after-cour","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648759314","pubTimestamp":1782861658,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"U.S. federal appellate court rules that Ardelyx’s Xphozah will be included in Medicare’s ESRD bundled payment system, ending separate reimbursement.\nThe decision resolves a long-running legal dispute over how the drug is treated under Medicare’s payment structure for dialysis care.\nThe ruling affects how dialysis providers are paid for Xphozah and may influence pricing decisions and product positioning for NasdaqGM:ARDX.\n\nArdelyx, the biopharmaceutical company behind Xphozah, focuses on...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ARDX":"Ardelyx"},"translate_title":"法院裁决后，Ardelyx(ARDX)面临Xphozah的新医疗保险规则","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1.5},"content_text":"U.S. federal appellate court rules that Ardelyx’s Xphozah will be included in Medicare’s ESRD bundled payment system, ending separate reimbursement. The decision resolves a long-running legal dispute over how the drug is treated under Medicare’s payment structure for dialysis care. The ruling affects how dialysis providers are paid for Xphozah and may influence pricing decisions and product positioning for NasdaqGM:ARDX.  Ardelyx, the biopharmaceutical company behind Xphozah, focuses on therapies for patients with kidney disease and related conditions. With the court placing Xphozah within Medicare’s end stage renal disease bundled payment framework, dialysis providers now face a different economic equation when deciding how and when to use the drug. This change links Xphozah more closely to overall dialysis treatment economics rather than leaving it as a separately reimbursed product. For investors tracking NasdaqGM:ARDX, the ruling reshapes assumptions around Medicare revenue potential and adoption patterns in dialysis centers. It also raises questions about how Ardelyx might adjust its commercial approach, including contracting with dialysis organizations and any future discussions with regulators and payers about product access and utilization incentives. Stay updated on the most important news stories for Ardelyx by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Ardelyx. NasdaqGM:ARDX 1-Year Stock Price Chart Is Ardelyx's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis. AdvertisementQuick Assessment  ✅ Price vs Analyst Target: Ardelyx trades at US$5.10 versus a US$16.30 consensus target, roughly 69% below analyst expectations. ✅ Simply Wall St Valuation: Shares are flagged as trading about 90.7% below an estimated fair value, suggesting a sizable valuation gap. ❌ Recent Momentum: The stock is down 15.6% over the past 30 days, showing weak recent sentiment despite the court decision.  There's only one way to know the right time to buy, sell or hold Ardelyx. Head to Simply Wall St's company report for the latest analysis of Ardelyx's Fair Value. Key Considerations  📊 The bundled payment ruling for Xphozah ties Ardelyx’s key product more tightly to dialysis provider economics. This could influence prescribing behavior and contracting terms. 📊 Watch how management discusses pricing, rebate structures, and uptake in large dialysis organizations, along with any updates on revenue contribution from Xphozah. ⚠️ The main flagged risk is significant insider selling over the past 3 months, which some investors may weigh alongside the current valuation signals.  Dig Deeper For the full picture including more risks and rewards, check out the complete Ardelyx analysis. Alternatively, you can check out the community page for Ardelyx to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648759314","isCrawlerRequest":true}